Application of Vina-ginsenoside R18 in preparation of anti-dengue virus pharmaceutical preparation

A pharmaceutical preparation, dengue virus technology, applied in the field of anti-virus, to achieve the effect of inhibiting replication, strong anti-dengue virus activity, and good medicinal prospects

Pending Publication Date: 2021-12-31
广东中诚生物科技有限公司
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Currently there is no effective vaccine or drug to prevent and treat diseases caused by dengue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Vina-ginsenoside R18 in preparation of anti-dengue virus pharmaceutical preparation
  • Application of Vina-ginsenoside R18 in preparation of anti-dengue virus pharmaceutical preparation
  • Application of Vina-ginsenoside R18 in preparation of anti-dengue virus pharmaceutical preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Toxicity of Vina-ginsenoside R18 to BHK-21 cells

[0037] Test method BHK-21 cells in the logarithmic growth phase were taken in 1×10 5 Cells / mL were inoculated in 96-well plates, 100 μL per well, and the control group and drug groups with different concentrations were set up. The cytotoxicity was detected by MTT method 4 days later.

[0038] figure 1 The test results of Vina-ginsenoside R18 showed that the half inhibitory concentration of Vina-ginsenoside R18 on BHK-21 cells was 54.11 μM, and it was basically non-toxic to cells at a concentration of 25 μM.

Embodiment 2

[0039] Example 2 Vina-ginsenoside R18 blocks the adsorption of type 2 dengue virus to host cells

[0040] Test method BHK-21 cells in the logarithmic growth phase were taken in 1×10 5 Cells / mL were seeded in a 96-well plate with 100 μL per well. The model group was infected with 200PFU of DENV-2, and the drug group was given 200PFU of DENV-2 and vina-ginsenoside R18 (6.25, 12.5, 25μM) at the same time. After incubation at 4°C for 1 hour, the virus and drug solution were discarded, and 2% maintenance solution was added. , placed in 37 ℃, 5% (v / v) CO 2 continue to grow in the incubator. After 4 days, the blocking effect of the drug on the adsorption of type 2 dengue virus to the host cells was determined by observing the cell lesions and death.

[0041] figure 2 The experimental results showed that Vina-ginsenoside R18 blocked the adsorption of dengue virus type 2 to host cells in a dose-dependent manner.

Embodiment 3

[0042] Example 3 Vina-ginsenoside R18 blocks type 2 dengue virus from entering host cells

[0043] Test method BHK-21 cells in the logarithmic growth phase were taken in 1×10 5 Cells / mL were seeded in a 96-well plate with 100 μL per well. The model group and the drug group were respectively infected with 200PFU of DENV-2, cultured at 4°C for 1 hour, discarded the virus, and the drug group was given vina-ginsenoside R18 (6.25, 12.5, 25μM), placed in 37°C, 5% (v / v )CO 2 Incubate for 1 h in an incubator. Afterwards, the drug solution was discarded, 2% maintenance solution was added, and the culture was continued in an incubator at 37°C. After 4 days, the blocking effect of the drug on the entry of type 2 dengue virus into the host cells was determined by observing the lesions and death of the cells.

[0044] image 3 The test results show that Vina-ginsenoside R18 can effectively block type 2 dengue virus from entering host cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Half inhibitory concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of a dammarane type tetracyclic triterpenoid monomeric compound vina-ginsenoside R18 in preparation of anti-dengue virus pharmaceutical preparation. In-vitro cell experiments of the compound show that the vina-ginsenoside R18 can play a role in resisting dengue virus through a plurality of links of blocking virus adsorption, entering host cells, inhibiting virus replication in the cells and the like, and has good antiviral activity. Therefore, the vina-ginsenoside R18 as an anti-dengue virus pharmaceutical preparation has a wide application prospect.

Description

technical field [0001] The invention relates to the application of vina-ginsenoside R18 in the preparation of anti-dengue virus drug preparations, belonging to the field of anti-virus technology. Background technique [0002] Dammarane-type tetracyclic triterpenoids are the main components of Araliaceae plants Panax ginseng and Panax notoginseng. Modern studies have shown that dammarane-type tetracyclic triterpenoids have various pharmacological effects such as anti-virus, anti-tumor, immune regulation, and anti-oxidation. Among them, in terms of anti-virus, such compounds can significantly inhibit hepatitis C virus (Hepatology, 2017, 66: 758-771), herpes simplex virus (Virologica Sinica, 2012, 27: 19-25), human immunodeficiency virus (Clinical and Vaccine Immunology, 2009, 16:1127-1131) and other virus replication. We isolated vina-ginsenosideR18, a dammarane-type tetracyclic triterpenoid monomer compound from Panax notoginseng, but no studies have reported its antiviral-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K45/06A61P31/14
CPCA61K31/704A61K45/06A61P31/14A61K2300/00Y02A50/30
Inventor 刘俊珊叶文才郑远茹陈建新范春林
Owner 广东中诚生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap